Crispr Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $889 | $892 | $865 | $35,000 |
Gross Profit | -63,804 | -45,153 | -56,644 | 35,000 |
EBITDA | -101,389 | -224,675 | -143,688 | -59,746 |
EBIT | -105,822 | -229,324 | -148,424 | -64,588 |
Net Income | -106,441 | -208,549 | -135,996 | -37,311 |
Net Change In Cash | 889 | 892 | 865 | 35,000 |
Free Cash Flow | -84,708 | -113,997 | -54,153 | -50,285 |
Cash | 286,497 | 197,132 | 235,184 | 298,257 |
Basic Shares | 91,305 | 87,069 | 85,938 | 85,464 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $35,000 | $370,000 | $436 | $913,081 |
Gross Profit | -75,250 | 239,750 | -109,814 | 913,081 |
EBITDA | -447,307 | -202,701 | -648,989 | 391,481 |
EBIT | -466,566 | -222,538 | -673,161 | 373,528 |
Net Income | -366,252 | -153,610 | -650,175 | 377,661 |
Net Change In Cash | 35,000 | 370,000 | 436 | 913,081 |
Cost of Revenue | -715,804 | -245,513 | ||
Free Cash Flow | -144,675 | -269,845 | -532,929 | 457,267 |
Cash | 298,257 | 389,477 | 211,885 | 923,031 |
Basic Shares | 84,359 | 79,220 | 77,746 | 80,393 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$1.17 |
2025-06-30 | -$1.29 |
2025-03-31 | -$1.58 |
